QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) Stock Competitors & Peer Comparison

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, ENTERO.NS has a market cap of 62B. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while ENTERO.NS trades at ₹1,423.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas ENTERO.NS's P/E ratio is 46.91. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to ENTERO.NS's ROE of +0.07%. Regarding short-term risk, QMSMEDI.NS is more volatile compared to ENTERO.NS. This indicates higher risk in terms of short-term price fluctuations for QMSMEDI.NS.Check ENTERO.NS's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, EVERESTO.BO has a market cap of 2.9B. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while EVERESTO.BO trades at ₹297.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas EVERESTO.BO's P/E ratio is 52.25. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to EVERESTO.BO's ROE of +0.07%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to EVERESTO.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check EVERESTO.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to ACHYUT.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check ACHYUT.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check RAMAVISION.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, QMSMEDI.NS is more volatile compared to BALAXI.NS. This indicates higher risk in terms of short-term price fluctuations for QMSMEDI.NS.Check BALAXI.NS's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, QMSMEDI.NS is more volatile compared to BIJHANS.BO. This indicates higher risk in terms of short-term price fluctuations for QMSMEDI.NS.Check BIJHANS.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check VIVOBIOT.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to RAJNISH.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check RAJNISH.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to CBPL.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check CBPL.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, MONOPHARMA.NS has a market cap of 149.3M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while MONOPHARMA.NS trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas MONOPHARMA.NS's P/E ratio is 4.83. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to MONOPHARMA.NS's ROE of N/A. Regarding short-term risk, QMSMEDI.NS is more volatile compared to MONOPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for QMSMEDI.NS.Check MONOPHARMA.NS's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, NEXUSSURGL.BO has a market cap of 106.6M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while NEXUSSURGL.BO trades at ₹19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas NEXUSSURGL.BO's P/E ratio is 228.86. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to NEXUSSURGL.BO's ROE of +0.56%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to NEXUSSURGL.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check NEXUSSURGL.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, QMSMEDI.NS is less volatile compared to NATURO.BO. This indicates lower risk in terms of short-term price fluctuations for QMSMEDI.NS.Check NATURO.BO's competition here

QMS Medical Allied Services Ltd. (NSE: QMSMEDI.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, QMSMEDI.NS stands at 2.9B. In comparison, EVOQ.BO has a market cap of 42.6M. Regarding current trading prices, QMSMEDI.NS is priced at ₹148.39 on the NSE, while EVOQ.BO trades at ₹1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

QMSMEDI.NS currently has a P/E ratio of 21.23, whereas EVOQ.BO's P/E ratio is -17.10. In terms of profitability, QMSMEDI.NS's ROE is N/A, compared to EVOQ.BO's ROE of -0.01%. Regarding short-term risk, QMSMEDI.NS is more volatile compared to EVOQ.BO. This indicates higher risk in terms of short-term price fluctuations for QMSMEDI.NS.Check EVOQ.BO's competition here